Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

Affiliations

¹ Department of Dermatology and Department of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA. Electronic address: emma.guttman@mountsinai.org.
² Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
³ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁴ Department of Dermatology, Kyoto University, Kyoto, Japan.
⁵ Department of Dermatology, Dokkyo Medical University, Tochigi, Japan.
⁶ Kyowa Kirin, Tokyo, Japan.
⁷ Kyowa Kirin International, London, UK.
⁸ Department of Dermatology, Kyushu University, Fukuoka, Japan.

Comment

Emma Guttman-Yassky et al. Lancet. 2023.

. 2023 Nov 18;402(10415):1834.

doi: 10.1016/S0140-6736(23)01618-5.

¹ Department of Dermatology and Department of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA. Electronic address: emma.guttman@mountsinai.org.
² Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
³ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁴ Department of Dermatology, Kyoto University, Kyoto, Japan.
⁵ Department of Dermatology, Dokkyo Medical University, Tochigi, Japan.
⁶ Kyowa Kirin, Tokyo, Japan.
⁷ Kyowa Kirin International, London, UK.
⁸ Department of Dermatology, Kyushu University, Fukuoka, Japan.

No abstract available

Comment on

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
Devjani S, Engel PV, Javadi SS, Smith B, Wu JJ. Devjani S, et al. Lancet. 2023 Nov 18;402(10415):1833-1834. doi: 10.1016/S0140-6736(23)01619-7. Lancet. 2023. PMID: 37980089 No abstract available.